TCM reported a consolidated net loss of ₹1.14 crore for the quarter ended December 2025, representing a 33% increase from the net loss of ₹0.86 crore recorded in the corresponding quarter of the previous year. According to reports from Business Standard, the company's financial performance showed deterioration across key metrics during the quarter. However, recent developments suggest TCM's financial trend score has improved from -7 to -2 over the last three months, indicating a shift from a deteriorating to a flat performance trajectory, as reported by MarketsMOJO.
The company's sales declined 7.93% to ₹5.69 crore in Q3 FY26, compared to ₹6.18 crore in the same quarter of the previous year. As reported by Business Standard, this revenue contraction contributed to the overall financial challenges faced by the company during the quarter. TCM's stock closed at ₹53.00 on February 16, 2026, down marginally by 0.32% from the previous close of ₹53.17, according to MarketsMOJO. The stock's 52-week trading range remains wide, with a high of ₹81.00 and a low of ₹35.00, highlighting significant volatility over the past year.
Operating profit margin (OPM) remained negative at -9.67% in Q3 FY26, compared to -9.71% in the corresponding quarter of the previous year. The company's PBDT (Profit Before Depreciation and Tax) turned negative at ₹1.00 crore, while PBT (Profit Before Tax) was ₹1.18 crore, showing a 31% decline from the previous year's ₹0.90 crore. According to MarketsMOJO, margin expansion remains limited with no significant improvement reported in operating or net margins for the quarter. The company's Mojo Score has improved to 33.0 as of February 16, 2026, up from a previous lower score, though the Mojo Grade remains at Sell on 5 January 2026, reflecting a cautious market outlook.
TCM's stock performance shows mixed results across different time horizons. Over the past week, the stock outperformed the Sensex with a gain of 2.42% compared to the Sensex's decline of 1.14%. However, year-to-date, the stock has declined by 17.37%, significantly worse than the Sensex's 3.04% fall. Over a one-year period, TCM has delivered a robust 21.03% return, outperforming the Sensex's 8.52% gain. The three-year return of 48.46% also surpasses the Sensex's 36.73%, demonstrating medium-term value delivery despite recent headwinds. However, the five-year return of 40.03% lags behind the Sensex's 60.30%, and the ten-year return is deeply negative at -41.27%, compared to the Sensex's strong 259.46% growth, highlighting long-term underperformance challenges.
